Aytu Bioscience (NASDAQ:AYTU) Research Coverage Started at Northland Securities

Northland Securities started coverage on shares of Aytu Bioscience (NASDAQ:AYTU) in a research note released on Friday, Stock Target Advisor reports. The firm issued a buy rating and a $5.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. LADENBURG THALM/SH SH lifted their price target on shares of Aytu Bioscience from $4.00 to $4.75 in a research report on Wednesday, September 18th. ValuEngine cut shares of Aytu Bioscience from a buy rating to a hold rating in a research report on Monday, November 11th. Finally, Zacks Investment Research cut shares of Aytu Bioscience from a buy rating to a hold rating in a research report on Thursday, October 3rd.

Shares of NASDAQ:AYTU traded down $0.04 during trading on Friday, hitting $0.79. 120,200 shares of the company’s stock were exchanged, compared to its average volume of 433,331. Aytu Bioscience has a 1-year low of $0.68 and a 1-year high of $2.61. The firm has a 50-day moving average price of $1.08 and a two-hundred day moving average price of $1.52. The firm has a market cap of $20.32 million, a P/E ratio of -0.23 and a beta of 4.63.

Aytu Bioscience (NASDAQ:AYTU) last issued its quarterly earnings results on Thursday, November 14th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Aytu Bioscience had a negative return on equity of 199.54% and a negative net margin of 390.43%. The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $1.45 million. On average, research analysts predict that Aytu Bioscience will post -0.64 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Aytu Bioscience during the 2nd quarter worth approximately $36,000. Bank of New York Mellon Corp bought a new position in Aytu Bioscience during the 2nd quarter worth approximately $75,000. Finally, Searle & CO. boosted its stake in Aytu Bioscience by 24.1% during the 3rd quarter. Searle & CO. now owns 249,848 shares of the company’s stock worth $302,000 after acquiring an additional 48,601 shares during the last quarter. 15.65% of the stock is currently owned by institutional investors and hedge funds.

Aytu Bioscience Company Profile

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

Recommended Story: What is the Hang Seng index?  

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.